Boston Scientific Corp (BSX)vsEquinix Inc (EQIX)
BSX
Boston Scientific Corp
$57.15
+0.80%
HEALTHCARE · Cap: $92.25B
EQIX
Equinix Inc
$1,089.07
+1.18%
REAL ESTATE · Cap: $109.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 123% more annual revenue ($20.61B vs $9.26B). BSX leads profitability with a 17.3% profit margin vs 14.6%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
EQIX
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-24.1%
Fair Value
$46.04
Current Price
$57.15
$11.11 premium
Margin of Safety
-38.5%
Fair Value
$626.41
Current Price
$1089.07
$462.66 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 21.5%
Generating 1.0B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 21.5%
Earnings expanding 22.9% YoY
Areas to Watch
Moderate valuation
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 21.5%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : EQIX
The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : EQIX
The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 80.7x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while EQIX is a value play — different risk/reward profiles.
EQIX carries more volatility with a beta of 1.00 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (71/100 vs 50/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Equinix Inc
REAL ESTATE · REIT - SPECIALTY · USA
Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?